Tumour metabolism: The promoter becomes the suppressor
Nature Reviews Cancer 18, 66 (2018).
doi:10.1038/nrc.2018.8
Author: Sarah Seton-Rogers
Somatic mutations in IDH1 or IDH2 are common in acute myeloid leukaemia (AML) and glioma, and result in a neomorphic enzyme that produces the metabolite R-2-hydroxyglutarate (R-2HG), which has been widely reported to have tumour-promoting activities. Su, Dong, Li et al. showed that
Source: Nature Reviews Cancer - Category: Cancer & Oncology Authors: Sarah Seton-Rogers Tags: Research Highlight Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Brain Tumor | Cancer | Cancer & Oncology | Glioma | Leukemia